Argenx Se (ARGX) Consolidated Net Income (2016 - 2026)
Argenx Se's (ARGX) quarterly Consolidated Net Income came in at $482.0 million in Q2 2026, up 248.37% YoY from $138.4 million in Q2 2025, and up 27.51% on a QoQ basis from $378.0 million in Q1 2026.
Analysis
Argenx Se (ARGX) Consolidated Net Income (2016 - 2026) Analysis & Trends
Argenx Se (ARGX) has 11 years of Consolidated Net Income data on file, last reported at $482.0 million in Q2 2026.
- Quarterly Consolidated Net Income rose 248.37% year-over-year to $482.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.8 billion (up 51.26% YoY) and the FY2025 annual result came in at $1.3 billion, down 17.42% from the prior year.
- Consolidated Net Income rose to $482.0 million in Q2 2026, from $378.0 million in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of $771.5 million in Q4 2024 to a low of -$241.3 million in Q1 2022.
- A 5-year average of $111.0 million and a median of $97500.0 in 2023 frame the typical range for Consolidated Net Income.
- Annual changes were most pronounced in 2022 — Consolidated Net Income slumped 1435.49% — and 2024, when it jumped 877.94%.
- Tracing ARGX's Consolidated Net Income over 5 years: stood at -$38.6 million in 2022, then plunged by 156.84% to -$99.2 million in 2023, then jumped by 877.94% to $771.5 million in 2024, then slumped by 30.92% to $532.9 million in 2025, then decreased by 9.56% to $482.0 million in 2026.
- The last three Consolidated Net Income figures came in at $482.0 million (Q2 2026), $378.0 million (Q1 2026), and $532.9 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn | 585.61 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 601.00 Mn |
| Mar 31, 2026 | 499.00 Mn |
| Dec 31, 2025 | 273.64 Mn |
| Sep 30, 2025 | 427.85 Mn |
| Jun 30, 2025 | 328.44 Mn |
| Mar 31, 2025 | 235.36 Mn |
| Dec 31, 2024 | -603.80 Mn |
| Sep 30, 2024 | 84.64 Mn |
| Jun 30, 2024 | -59.07 Mn |
| Mar 31, 2024 | -87.10 Mn |
| Dec 31, 2023 | -23.18 Mn |
| Sep 30, 2023 | -93.92 Mn |
| Jun 30, 2023 | -73.35 Mn |
| Mar 31, 2023 | -123.49 Mn |
| Dec 31, 2022 | -43.86 Mn |
| Sep 30, 2022 | -247.01 Mn |
| Jun 30, 2022 | -225.21 Mn |
| Mar 31, 2022 | -232.96 Mn |
| Dec 31, 2021 | -251.94 Mn |
| Sep 30, 2021 | -228.12 Mn |